Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biopharmas Escape 'Death Panel,' But 2017 Lurks

Executive Summary

Investors drove shares of biopharmaceutical companies up on June 22 on the news the projected growth rate in Medicare spending did not exceed the threshold needed this year to trigger the so-called Independent Payment Advisory Board (IPAB) to make recommendations for curbing spending. Republicans are opposed to the IPAB, calling it an "unelected and unaccountable board of bureaucrats," with some even dubbing it a "death panel."

Advertisement

Related Content

Divide Runs Deep Over Medicare B Drug Payment Experiment
PhRMA Condemns Medicare B Rx Drug Payment Experiment
HHS: ACA saved seniors $11.5bn on Rx drugs
Trustees: Without reforms, Medicare on 'unsustainable path'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel